| Nov 15 |
Femasys Third Quarter 2024 Earnings: Misses Expectations
|
| Nov 12 |
Femasys GAAP EPS of -$0.24, revenue of $554.91M
|
| Nov 12 |
Femasys Inc. (FEMY) Reports Q3 Loss, Tops Revenue Estimates
|
| Nov 12 |
Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update
|
| Nov 7 |
Femasys to Exhibit at the Annual AAGL 2024 Global Conference
|
| Nov 1 |
Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control
|
| Oct 30 |
Femasys Announces Partnership with Boston IVF, Prominent Network of Fertility Centers, to Offer FemaSeed
|
| Oct 10 |
Femasys to Exhibit at ASRM 2024 and Participate in the Congress’ KEEPR Education Program
|
| Oct 8 |
Femasys to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
|
| Oct 2 |
Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments
|
